Jiangsu Aidea Pharmaceutical Group Co., Ltd. (SHA:688488)
17.50
+0.74 (4.42%)
Feb 13, 2026, 3:00 PM CST
SHA:688488 Revenue
Jiangsu Aidea Pharmaceutical Group had revenue of 189.92M CNY in the quarter ending September 30, 2025, with 61.21% growth. This brings the company's revenue in the last twelve months to 671.33M, up 64.27% year-over-year. In the year 2024, Jiangsu Aidea Pharmaceutical Group had annual revenue of 417.80M with 1.57% growth.
Revenue (ttm)
671.33M
Revenue Growth
+64.27%
P/S Ratio
10.97
Revenue / Employee
953.59K
Employees
683
Market Cap
7.36B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 417.80M | 6.44M | 1.57% |
| Dec 31, 2023 | 411.36M | 167.14M | 68.44% |
| Dec 31, 2022 | 244.22M | -11.49M | -4.49% |
| Dec 31, 2021 | 255.71M | -33.35M | -11.54% |
| Dec 31, 2020 | 289.06M | -56.17M | -16.27% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Suzhou Fengbei Biotech Stock | 2.81B |
| Novogene | 2.17B |
| Xiangxue Pharmaceutical | 1.47B |
| Shenzhen Weiguang Biological Products | 1.14B |
| Wuhan Keqian Biology Co.,Ltd | 1.01B |
| Beijing Konruns Pharmaceutical | 871.31M |
| GemPharmatech | 793.25M |
| R&G PharmaStudies | 789.45M |